Protective Cell-Mediated Immunity by DNA Vaccination against Papillomavirus L1 Capsid Protein in the Cottontail Rabbit Papillomavirus Model

• Published in: Viral Immunology 2006, Vol.19 (3), p.492-507
• Main Authors: Hu, Jiafen, Cladel, Nancy M., Budgeon, Lynn R., Reed, Cynthia A., Pickel, Martin D., Christensen, Neil D.
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Viral - blood; Antigens, Viral - administration & dosage; Antigens, Viral - genetics; Antigens, Viral - immunology; Antigens, Viral - metabolism; Cell Line; Cottontail rabbit papillomavirus; Cottontail rabbit papillomavirus - immunology; Cottontail rabbit papillomavirus - pathogenicity; Disease Models, Animal; Immunity, Cellular; Papillomavirus; Papillomavirus Infections - immunology; Papillomavirus Infections - prevention & control; Rabbit oral papillomavirus; Rabbits; T-Lymphocytes - immunology; Tumor Viruses; Vaccination; Vaccines, DNA - administration & dosage; Vaccines, DNA - immunology; Viral Structural Proteins - administration & dosage; Viral Structural Proteins - genetics; Viral Structural Proteins - immunology; Viral Structural Proteins - metabolism; Viral Vaccines - administration & dosage; Viral Vaccines - genetics; Viral Vaccines - immunology
• ISSN: 0882-8245; 1557-8976; 1365-2567
• DOI: 10.1089/vim.2006.19.492

Papillomavirus major capsid protein L1 has successfully stimulated protective immunity against virus infection by induction of neutralizing antibodies in animal models and in clinical trials. However, the potential impact of L1-induced protective cell-mediated immune (CMI) responses is difficult to measure in vivo because of the coincidence of anti-L1 antibody. In this study, we tested the hypothesis that L1 could activate CMI, using the Cottontail Rabbit Papillomavirus (CRPV)-rabbit model. A unique property of this model is that infections can be initiated with viral DNA, thus bypassing all contributions to protection via neutralizing anti-L1 antibody. DNA vaccines containing either CRPV L1, or subfragments of L1 (amino-terminal two-thirds of L1 [L1N] and the carboxylterminal two-thirds of L1 [L1C]), were delivered intracutaneously into rabbits, using a gene gun. After three booster immunizations, the rabbits were challenged with several viral DNA constructs: wild-type CRPV, CRPV L1ATGko (an L1 ATG knockout mutation), and CRPV-ROPV hybrid (CRPV with a replacement L1 from Rabbit Oral Papillomavirus). Challenge of L1 DNA-vaccinated rabbits with wild-type CRPV resulted in significantly fewer papillomas when compared with challenge with CRPV L1ATGko DNA. Significantly smaller papillomas were found in CRPV L1-, L1N-, and L1C-vaccinated rabbits. In addition, rabbits vaccinated with either L1 or L1N grew significantly fewer and smaller papillomas when challenged with CRPV-ROPV hybrid DNA. Therefore, CRPV L1 DNA vaccination induced CMI responses to CRPV DNA infections that can contribute to protective immunity. Cross-protective immunity against CRPV L1 and ROPV L1 was elicited in these CRPV L1- and subfragment-vaccinated rabbits.